Nurix Therapeutics 

Yahoo Finance • yesterday

Stocks Climb as Dovish Fed Comments Knock Bond Yields Lower

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +0.32%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q... Full story

Yahoo Finance • yesterday

Nurix Therapeutics GAAP EPS of -$1.03 misses by $0.11, revenue of $7.9M misses by $4.33M

* Nurix Therapeutics press release [https://seekingalpha.com/pr/20261446-nurix-therapeutics-reports-third-quarter-2025-financial-results-and-provides-a-corporate] (NASDAQ:NRIX [https://seekingalpha.com/symbol/NRIX]): Q3 GAAP EPS of -$1.0... Full story

Yahoo Finance • 2 days ago

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical data at EADV 2025 for GS-6791 (NX-0479), a novel IRAK4 degrader in collaboration... Full story

Yahoo Finance • last month

Nurix Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, t... Full story

Yahoo Finance • 3 months ago

Nurix Therapeutics price target lowered to $34 from $36 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Nurix Therapeutics (NRIX) to $34 from $36 and keeps a Buy rating on the shares. Nurix last week reported a Q2 net loss of (52c) per share, slightly narrower than the firm’s previously esti... Full story

Yahoo Finance • 3 months ago

Morgan Stanley lowers Nurix stock price target to $16 on higher spend

Investing.com - Morgan Stanley lowered its price target on Nurix (NASDAQ:NRIX) to $16.00 from $17.00 on Monday, while maintaining an Equalweight rating on the biotechnology company’s stock. With the stock currently trading at $12.72, analy... Full story

Yahoo Finance • 3 months ago

Goldman Sachs initiates Nurix stock with Buy rating, $182 price target

Investing.com - Goldman Sachs initiated coverage on Nurix (NASDAQ:NRIX) with a Buy rating and set a price target of $182.00. Currently trading at $13.18, the stock has shown significant volatility with a beta of 2.15. According to Investin... Full story

Yahoo Finance • 3 months ago

Nurix earnings beat by $0.19, revenue topped estimates

Investing.com - Nurix (NASDAQ: NRIX) reported second quarter EPS of $-0.52, $0.19 better than the analyst estimate of $-0.71. Revenue for the quarter came in at $44.06M versus the consensus estimate of $16.9M. Nurix’s stock price closed a... Full story

Yahoo Finance • 3 months ago

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM) Secu... Full story

Yahoo Finance • 3 months ago

Nurix stock maintains Buy rating at H.C. Wainwright on positive BTK degrader data

Investing.com - H.C. Wainwright has reiterated a Buy rating on Nurix (NASDAQ:NRIX) with a price target of $36.00 following the company’s presentation of updated clinical data at the European Hematology 2025 annual meeting. Currently tradin... Full story

Yahoo Finance • 4 months ago

Nurix Therapeutics' SWOT analysis: promising BTK degrader stock faces challenges

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company focused on developing novel therapies for cancer and immune disorders, has been garnering attention from investors and analysts alike. According to InvestingPro data, the... Full story

Yahoo Finance • 4 months ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, t... Full story

Yahoo Finance • 4 months ago

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study or higher doses D... Full story

Yahoo Finance • 4 months ago

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, t... Full story

Yahoo Finance • 4 months ago

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU, and a promising... Full story

Yahoo Finance • 4 months ago

Sanofi Exercises License Extension Option to Nurix’s STAT6 Program

STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from Sanofi under its 2019 collaboration agreement... Full story

Yahoo Finance • 6 months ago

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

NX-5948 assigned the nonproprietary name “bexobrutideg” U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemia Achieved $7M in milestones and a $15M license extension fee from ongoing co... Full story

Yahoo Finance • 7 months ago

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines,... Full story

Yahoo Finance • 7 months ago

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

SAN FRANCISCO, March 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines,... Full story

Yahoo Finance • 8 months ago

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, t... Full story